newsfilter
← Latest News
GlobeNewswire·

Aravive Reports Third Quarter 2022 Financial Results and Provides Corporate Updates

Continued Advancement of Clinical Trials in Platinum Resistant Ovarian Cancer (PROC), Clear Cell Renal Cell Carcinoma and Pancreatic AdenocarcinomaSecured Funding to Take the Company Beyond the PROC Readout in